Off-label prescribing for children still widespread despite EU Paediatric Regulation
This article was originally published in Scrip
The lack of medicines approved specifically for children is in the spotlight again, with a report from the European Medicines Agency saying that off-label prescribing is still widespread in the EU, despite the fact that the practice is associated with more adverse events in children than in adults.
You may also be interested in...
As part of its efforts to preserve patient access to medicines amid the COVID-19 pandemic, Russia is planning to cap drug prices if increases of more than 30% are detected. It will also allow online sales of non-prescription drugs and may also tighten the rules on fake and substandard products.
France is exploring the use of hydroxychloroquine and lopinavir/ritonavir in COVID-19, but only in hospitalized patients and in clinical trials, and has banned all exports of the products to avoid possible shortages.
Efforts are under way in the UK on many fronts to develop new treatments and vaccines for coronavirus infection, including researching new uses of existing products and clinical trials of new vaccines.